Methods of treating psoriasis with secukinumab
Summary
The USPTO granted patent US12594332B2 to Novartis AG covering novel regimens for treating psoriasis using secukinumab, an IL-17 antibody antagonist. The patent includes 11 claims directed to therapeutic methods employing the antibody. The patent application was filed on December 16, 2024, with inventors including Achim Guettner, Matthias Machacek, Charis Papavassilis, and Oliver Sander.
What changed
The USPTO issued patent US12594332B2 to Novartis AG on April 7, 2026, covering methods of treating psoriasis using secukinumab, an IL-17 antagonist antibody. The patent contains 11 claims and is classified under CPC codes A61K 39/3955, A61K 2039/505, and A61P 17/06. The invention disclosure describes novel dosing regimens employing secukinumab for therapeutic applications.
Pharmaceutical companies developing biosimilar IL-17 inhibitors or generic psoriasis treatments should assess whether their products or methods fall within the scope of these claims. The patent provides Novartis with exclusivity in the United States for secukinumab treatment methods, which may affect competitive entry strategies and licensing negotiations for other IL-17 targeting therapies.
What to do next
- Monitor for infringement of US12594332B2 patent claims covering secukinumab psoriasis treatment methods
- Review freedom-to-operate for any psoriasis treatment regimens involving IL-17 antagonists
Archived snapshot
Apr 7, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
Methods of treating psoriasis with secukinumab
Grant US12594332B2 Kind: B2 Apr 07, 2026
Assignee
NOVARTIS AG
Inventors
Achim Guettner, Matthias Machacek, Charis Papavassilis, Oliver Sander
Abstract
The disclosure relates to novel regimens for treating psoriasis, which employ a therapeutically effective amount of an IL-17 antagonist, e.g., an IL-17 binding molecule, e.g., an IL-17 antibody, such as the secukinumab antibody, or an IL-17 receptor binding molecule, e.g., an IL-17 receptor antibody.
CPC Classifications
A61K 39/3955 A61K 2039/505 A61P 17/06
Filing Date
2024-12-16
Application No.
18983037
Claims
11
Related changes
Get daily alerts for USPTO Patent Grants - Therapeutics (A61P)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from USPTO.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when USPTO Patent Grants - Therapeutics (A61P) publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.